119th Congress Health
S. 832: EPIC Act of 2025
Introduced
- Introduced (completed)
- Passed Senate (not reached)
- Passed House (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.
The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Cosponsors
- Marsha Blackburn R-TNOriginal
- Ted Budd R-NCOriginal
- Steve Daines R-MTOriginal
- James Lankford R-OKOriginal
- John Curtis R-UT
- Jim Banks R-IN
- Roger Marshall R-KS
Who scored on this bill
No member has earned points from it yet.
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
Other bills by Thom Tillis
History
- Introduced in the Senate by Thom Tillis.
Show the full action history (2 actions)
- Introduced in Senate
- Read twice and referred to the Committee on Finance.